A RETROSPECTIVE case series has identified ophthalmic complications in patients using the antidiabetic drugs semaglutide and ...

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Hydreight Technologies Inc. (“Hydreight”or the “Company”)(TSXV: NURS)(OTCQB: HYDTF)(FSE: SO6), a fast-growing mobile clinical network and medical platform which ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...

All physicians are faced with the challenge of how to help patients with no approved therapies for their diseases. What are ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...